Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)
Heze, CN
Shandong Buchang Pharmaceuticals Co., Ltd. is actively involved in China's pharmaceutical sector, specializing in the innovation, production, and distribution of medicinal products. The company provides a diverse range of treatments addressing various health conditions, including cardiovascular, cerebrovascular, urinary, digestive, and respiratory disorders, alongside gynecological problems and diabetes. Founded in 1993, this enterprise maintains its headquarters in Heze, China. Notably, it once operated as a subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.08% | -2.29% | -8.29% | -12.59% | -12.02% | -4.54% | -10.60% | -34.05% | -36.55% | -68.65% | -68.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.9% ★ Q1'26: -7.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+166.7% ★ Q1'26: +3.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.9% Q1'26: +2.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.1% Q1'26: +16.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.9% Q1'26: +10.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.5% ★ Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.24× Q1'26: 2.71× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.07% | 24.4K | 0.65% |
| 2 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 62.3K | 0.24% |
| 3 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 62.3K | 0.24% |
| 4 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 10.2K | 0.58% |
| 5 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 334.3K | 0.06% |
| 6 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 51.2K | 0.46% |
| 7 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 13.0K | 0.44% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 95.6K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 95.6K | 0.17% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 136.8K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bao Cai Wang | Vice President | — | male |
| Chao Zhao | President & Director | — | male |
| Haiqin Wu | Chairman of the Academic Committee | — | — |
| Kai Cheng | Accounting Supervisor | — | — |
| Ren Hui Xue | Vice President of Marketing & Director | — | male |
| Wei Jun Li | Vice President of Administration & Human Resources | — | male |
| Xiaogang Zhao | Chief Financial Officer | — | male |
| Xin Wang | Director & Secretary | — | female |
| Yi Min Wang | Executive Vice President & Vice Chairman | — | male |
| Zhao Buchang | Founder | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603858.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
